论文部分内容阅读
目的分析血液筛查Roche Cobas s201核酸检测系统非特异扩增曲线产生的原因。方法统计本室2014年10月-2015年12月用Cobas Taq Screen MPX v2.0核酸试剂检测产生非特异扩增曲线的次数,探讨其发生与时间、检测系统(A、B和C系统)和试剂批号(批号1、批号2、批号3、批号4、批号5和批号6)之间的关系。结果本室核酸检测非特异扩增曲线总发生率为0.386%(86/2 228);不同月份(χ~2=27.325,P<0.05)、不同检测系统(χ~2=66.305,P<0.05)和不同批号试剂(χ~2=129.550,P<0.05)之间的非特异扩增曲线发生率均有差异,其中2015年2月份、C检测系统和试剂批号2的发生率在各分项中均最大,分别为0.893%(10/1 120)、3.17%(10/315)和5.26%(10/190);非特异扩增曲线类型中以HCV曲线出现47次最多,占54.65%(47/86)。结论核酸检测非特异扩增曲线的发生与检测系统和试剂批号有明显相关性,加强对检测系统的管理和试剂确认管理能够提高核酸检测性能。
Objective To analyze the cause of non-specific amplification curve of blood screening Roche Cobas s201 nucleic acid detection system. Methods Statistics The number of non-specific amplification curves detected by Cobas Taq Screen MPX v2.0 nucleic acid reagent from October 2014 to December 2015 in our hospital was used to investigate the relationship between the occurrence and time, detection system (A, B and C systems) and Reagent lot numbers (lot 1, lot 2, lot 3, lot 4, lot 5, and lot 6). Results The total detection rate of non-specific amplification of nucleic acid was 0.386% (86/2 228) in different months (χ ~ 2 = 27.325, P <0.05) ) And different batches of reagents (χ ~ 2 = 129.550, P <0.05). In February 2015, the incidence of C detection system and reagent lot number 2 was significantly lower in all sub-items Were the largest, accounting for 0.893% (10/1 120), 3.17% (10/315) and 5.26% (10/190), respectively. The non-specific amplification curve showed 47 times with HCV curve (54.65%) 47/86). Conclusion The detection of nonspecific amplification curves by nucleic acid detection is significantly related to the detection system and reagent lot number. Enhancing the management of the detection system and reagent validation management can improve the performance of nucleic acid detection.